Pfizer (PFE) Depreciation & Amortization (CF) (2009 - 2026)

Pfizer (PFE) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) changed 0.18% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $6.6 billion, a 22.22% decrease from a year earlier, with the FY2025 full-year figure at $6.6 billion, down 6.0% from the prior year.
• Depreciation & Amortization (CF) was $1.6 billion for Q2 2026 at Pfizer, up from $1.6 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.2 billion in Q3 2024 and troughed at $1.2 billion in Q3 2022.
• A 5-year average of $1.8 billion and a median of $1.6 billion in 2025 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 33.87% in 2023 and slumped 68.17% in 2025, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.2 billion in 2022, then soared by 42.13% to $1.7 billion in 2023, then soared by 212.69% to $5.2 billion in 2024, then sank by 67.69% to $1.7 billion in 2025, then decreased by 3.85% to $1.6 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.7 billion (Q4 2025), per Business Quant data.